PL 3994

Drug Profile

PL 3994

Alternative Names: PL-3994

Latest Information Update: 14 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palatin Technologies
  • Class Natriuretic peptides
  • Mechanism of Action Atrial natriuretic factor receptor A agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Phase II Heart failure
  • Phase I Acute asthma

Most Recent Events

  • 14 Oct 2015 Palatin Technologies plans a phase II trial for Heart failure in USA
  • 19 Jun 2015 PL 3994 is still in phase-II development for Heart failure and phase-I for Asthma
  • 01 Dec 2014 Palatin Technologies terminates phase II trial in Asthma in USA (NCT01304628) prior to initiation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top